- Home
- LIDRW vs TNGX Comparison
LIDRW vs TNGX Comparison
Compare LIDRW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDRW
- TNGX
- Stock Information
- Founded
- LIDRW N/A
- TNGX 2014
- Country
- LIDRW United States
- TNGX United States
- Employees
- LIDRW 60
- TNGX N/A
- Industry
- LIDRW Auto Parts:O.E.M.
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LIDRW Consumer Discretionary
- TNGX Health Care
- Exchange
- LIDRW Nasdaq
- TNGX Nasdaq
- Market Cap
- LIDRW N/A
- TNGX 735.0M
- IPO Year
- LIDRW 2021
- TNGX N/A
- Fundamental
- Price
- LIDRW $0.01
- TNGX $6.64
- Analyst Decision
- LIDRW
- TNGX Strong Buy
- Analyst Count
- LIDRW 0
- TNGX 8
- Target Price
- LIDRW N/A
- TNGX $15.14
- AVG Volume (30 Days)
- LIDRW N/A
- TNGX 885.7K
- Earning Date
- LIDRW N/A
- TNGX 11-06-2024
- Dividend Yield
- LIDRW N/A
- TNGX N/A
- EPS Growth
- LIDRW N/A
- TNGX N/A
- EPS
- LIDRW N/A
- TNGX N/A
- Revenue
- LIDRW N/A
- TNGX $42,509,000.00
- Revenue This Year
- LIDRW N/A
- TNGX $18.15
- Revenue Next Year
- LIDRW N/A
- TNGX N/A
- P/E Ratio
- LIDRW N/A
- TNGX N/A
- Revenue Growth
- LIDRW N/A
- TNGX 26.16
- 52 Week Low
- LIDRW N/A
- TNGX $6.33
- 52 Week High
- LIDRW N/A
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- LIDRW 49.28
- TNGX 37.15
- Support Level
- LIDRW $0.01
- TNGX $6.83
- Resistance Level
- LIDRW $0.01
- TNGX $7.47
- Average True Range (ATR)
- LIDRW 0.00
- TNGX 0.37
- MACD
- LIDRW 0.00
- TNGX 0.11
- Stochastic Oscillator
- LIDRW 53.33
- TNGX 27.31
About LIDRW AEye Inc. Warrant
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.